Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2014 Dec 27;149(2):467–477. doi: 10.1007/s10549-014-3251-9

Table 3.

Correlation of TGF-βRII and pSmad2 expression with invasiveness of breast cancer, Shanghai Breast Cancer Study, Phase II

TGF-βRII intensity
TGFβ-RII subcellular pattern
pSmad2 intensity
0–1 2 3 P 1c 2d P 0–1 2 3 P
Adjacent normal breast tissue
 Number 24 212 570 664 142 312 231 261
 % 3.0 26.3 70.7 82.4 17.6 38.8 28.7 32.5
Non-invasive, in situ carcinomaa
 Number 3 28 59 24 66 17 34 39
 % 3.3 31.1 65.6 26.7 73.3 18.9 37.8 43.3
In situ with invasive carcinomaa
In situ component
 Number 18 93 220 120 211 61 109 161
 % 5.4 28.1 66.5 36.3 63.8 18.4 32.9 48.6
Invasive component
 Number 20 126 185 64 267 56 95 180
 % 6.0 38.1 55.9 19.3 80.7 16.9 28.7 54.4
Invasive carcinomab
 Number 74 275 275 95 529 124 182 318
 % 11.9 44.1 44.1 <0.01 15.2 84.8 <0.01 19.9 29.2 51.1 <0.01
a

Including ISDC and ISLC

b

Including IDC, ILC and Others

c

Membranous predominant

d

Cytoplasmic or membranous cytoplasmic